BAJAJ BROKING
Zydus Lifesciences has announced its consolidated financial results for the third quarter of FY24-25, reporting total revenue from operations of ₹5,269.1 million and a net profit of ₹1,023.5 crore. The company recorded a profit before tax (PBT) of ₹1,184.1 crore, with total expenses amounting to ₹4,142.5 crore. Key financial components include finance costs of ₹32 crore and other expenses of ₹1,534.2 crore. The pharmaceuticals segment contributed ₹4,809.9 crore in revenue, while the consumer products segment added ₹459.2 crore. These results underscore the company's strong financial performance and operational efficiency for the quarter.
Total Revenue from Operations: ₹5,269.1 crore, up 17% from last year.
Net Profit: ₹1,023.5 crore, up 30% over last year.
Profit Before Tax (PBT): ₹1,184.1 crore
Finance Costs: ₹32 crore
Other Expenses: ₹1,534.2 crore
Total Expenses: ₹4,142.5 crore
Segment Contribution:
Pharmaceuticals Revenue: ₹4,809.9 crore
Consumer Products Revenue: ₹459.2 crore
Zydus Lifesciences posted strong revenue growth in Q3 FY24-25, showcasing its resilience and strategic execution. The company’s total revenue stood at ₹5,269.1 crore, marking a notable increase compared to the previous year’s ₹4,505.2 crore.
The net profit for the quarter came in at ₹1,023.5 crore, reflecting solid bottom-line growth. The company’s cost management and operational efficiencies contributed to the overall profitability.
Revenue: ₹4,809.9 crore
Profit Before Tax: ₹1,175.3 crore
Steady growth across key product categories
Revenue: ₹459.2 crore
Profit Before Tax: ₹8.8 crore
Continued expansion in consumer health business
The pharmaceutical sector recorded total revenue from operations of ₹5,269.1 crore in Q3 FY24-25. Zydus Lifesciences reported a profit before tax (PBT) of ₹1,184.1 crore, with a net profit of ₹1,023.5 crore. The pharmaceuticals segment contributed ₹4,809.9 crore, while the consumer products segment accounted for ₹459.2 crore. The company's operational efficiencies and global sales have bolstered its financial performance this quarter.
Zydus Lifesciences, a global life sciences company engaged in the discovery, development, manufacturing, and marketing of a range of healthcare therapies, reported its financial results for the third quarter, outlining performance across its business segments. The company recorded contributions from both the pharmaceuticals and consumer products segments, with key financial metrics remaining in line with the previous quarter. As part of the Zydus Group, which employs over 27,000 people worldwide, the company continues its operations in healthcare solutions and maintains a presence in global markets.
Particulars | Q3 FY24-25 (₹ Crore) | Q2 FY24-25 (₹ Crore) | Q3 FY23-24 (₹ Crore) |
Revenue from Operations | 5,269.1 | 5,237 | 4,505.2 |
Profit Before Tax (PBT) | 1,184.1 | 1,270.9 | 925.5 |
Net Profit | 1,023.5 | 911.2 | 789.6 |
Total Expenses | 4,142.5 | 4,034.3 | 3,617.4 |
Depreciation and Amortisation | 229 | 233.6 | 194.8 |
Finance Costs | 32 | 25.1 | 19.8 |
Other Expenses | 1,534.2 | 1,470.4 | 1,137.6 |
Pharmaceuticals Revenue | 4,809.9 | 4,747.5 | 4,105.3 |
Consumer Products Revenue | 459.2 | 489.5 | 399.9 |
Source: Zydus Lifesciences' Financial Data submitted to BSE.
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Life Insurance Corporation of India Q3 Results FY24-25 Highlights
07 Feb, 2025 | 5 Min. read
Stock Market Live Updates | 07 Feb 2025
07 Feb, 2025 | 9 Min. read
Stock Market Live Updates | 06 Feb 2025
06 Feb, 2025 | 9 Min. read
Trent Q3 Results FY24-25 Highlights
06 Feb, 2025 | 4 Min. read
Info Edge Q3 Results FY24-25 Highlights
05 Feb, 2025 | 4 Min. read
Stock Market Live Updates | 05 Feb 2025
05 Feb, 2025 | 9 Min. read
Zydus Lifesciences Q3 Results FY24-25 Highlights
05 Feb, 2025 | 3 Min. read
Page Industries Q3 Results FY24-25 Highlights
05 Feb, 2025 | 4 Min. read
Hero MotoCorp Q3 Results FY24-25 Highlights
05 Feb, 2025 | 5 Min. read
State Bank of India Q3 Results FY24-25 Highlights
05 Feb, 2025 | 2 Min. read
Stock Market Live Updates | 04 Feb 2025
04 Feb, 2025 | 10 Min. read
Titan Q3 Results FY24-25 Highlights
03 Feb, 2025 | 2 Min. read
Analysis to Become a Pro Investor
28 Dec, 2023 | 4 Min. read
Women In Real Estate Investing (Investree)
28 Dec, 2023 | 5 Min. read
How To Check Prudent Corporate Advisory IPO Allotment Status
27 Dec, 2023 | 3 Min. read
How To Boost Credit Score? – Steps to Improve Creditworthiness
27 Dec, 2023 | 4 Min. read
Advantages and Disadvantages of Opening Multiple Demat Accounts
26 Dec, 2023 | 4 Min. read
7th CPC LTC: Leave Travel Concession Rules for Central Government Employees
26 Dec, 2023 | 4 Min. read
7th Pay Commission: House Building Advance (HBA) Interest Rate FY 2023-24
26 Dec, 2023 | 5 Min. read
The Future of Trading: Exploring Bajaj Broking’s Demat Features
26 Dec, 2023 | 6 Min. read
7th Central Pay Commission Cpc Fitment Table
23 Dec, 2023 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading